Search

Displaying results 5061 - 5070 of 10000 in total
  1. Drug

    Ciglitazone

    go.drugbank.com/drugs/DB09201
    Experimental

    Ciglitazone is a potent and selective PPARγ ligand with an EC50 of 3.0 µM. It is also an anti-hyperglycemic agent in the ob/ob murine model in vivo. … Ciglitazone was never used as a medication, but it sparked interest in the effects of thiazolidinediones.

  2. Drug

    Dehydroascorbic acid

    go.drugbank.com/drugs/DB08830
    Experimental

    Dehydroascorbic acid as well as ascorbic acid are both termed Vitamin C, but the latter is the main form found in humans. … Currently dehydroascorbic acid is an experimental drug with no known approved indications.

  3. Drug

    Nadide

    go.drugbank.com/drugs/DB14128
    Investigational

    It is found widely in nature and is involved in numerous enzymatic reactions in which it serves as an electron carrier by being alternately oxidized (NAD+) and reduced (NADH). (Dorland, 27th ed) … A coenzyme composed of ribosylnicotinamide 5'-diphosphate coupled to adenosine 5'-phosphate by pyrophosphate linkage.

  4. Drug

    Levomenol

    go.drugbank.com/drugs/DB13153
    Approved

    Bisabolol, or more formally α-(−)-bisabolol or also known as levomenol, (-)-alpha-Bisabolol is found in fats and oils. (-)-alpha-Bisabolol is isolated from essential oil of Matricaria chamomilla (German

  5. Drug

    Voglibose

    go.drugbank.com/drugs/DB04878
    Investigational

    Voglibose is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus.

  6. Drug

    Burosumab

    go.drugbank.com/drugs/DB14012
    ApprovedInvestigational

    XLH is a serious disease which affects about 3,000 children and 12,000 adults in the United States. … It causes impaired bone growth and development in children and adolescents and issues with bone mineralization throughout a patient’s life [L2346].

  7. Drug

    Lurbinectedin

    go.drugbank.com/drugs/DB12674
    ApprovedInvestigational

    the substitution of the tetrahydroisoquinoline with a tetrahydro β‐carboline that results in increased antitumour activity of lurbinectedin as compared to its predecessor. … Lurbinectedin is a DNA alkylating agent that has been investigated in the treatment of a variety of cancers, including mesothelioma,[A214325] chronic lymphocytic leukemia (CLL),[A214328] breast cancer,

  8. Drug

    Tunicamycin

    go.drugbank.com/drugs/DB13172
    Experimental

    Tunicamycin blocks N-linked glycosylation (N-glycans) resulting in cell cycle arrest at the G1 phase in human cells. It is used as an experimental tool to induce unfolded protein response. … Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes.

  9. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin. … Reviparin has a molecular weight of 3.9 kDa.[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469]

    Products: CLIVARIN 5726 IE A XA/ML, CLIVARODI 17178 A XA/ML
  10. Drug

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10799
    ApprovedInvestigational

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria